ABSTRACT
Sexual dysfunction (SD) is a common problem encountered in recipients of chemotherapy (CT), radiotherapy (RT), and chemo-radiotherapy (CRT) (1). CT (2) and RT (3) are commonly used for cancer of the pelvis, abdominal, and genital organs such as germ-and nongerm-cell tumors of testis, prostate, colorectal, and anal renal cancers (2). Other malignancies of the hematological system (lymphoma, leukemia, and myeloma), sarcoma, and bone tumors also constitute a large group of the recipients of CT, RT, and CRT (3).
